Updated:
Shanghai INT Medical Instruments
Shanghai INT Medical Instruments was established in 2006 by Dr. Liang Dongke, who continues to lead the firm as Chairman and General Manager.
Shanghai INT Medical Instruments
Shanghai INT Medical Instruments was established in 2006 by Dr. Liang Dongke, who continues to lead the firm as Chairman and General Manager. It operates as a corporate investor structured around a publicly listed operating company (HKEX: 1501) that channels capital into 24 controlled subsidiaries. Major institutional shareholders include China Orient Asset Management (13.52% stake) and OrbiMed Advisors, a specialist global healthcare investment firm. INT Medical deploys capital primarily through wholly owned subsidiaries and limited-partner commitments in life-science funds. Its operating business designs, develops, and sells interventional medical instruments — including cardiac, peripheral-vascular, neurovascular, urological, and orthopedic devices — to over 90 countries. The firm holds 120 domestic product registrations, 43 CE marks, and 26 FDA clearances. Confirmed LP commitments include life-science funds managed by Ningbo Huaige Health Investment Management Partnership. OrbiMed's role as both shareholder and co-investor further embeds INT Medical in the global medtech capital network. The group employs more than 2,000 people across three manufacturing and research bases in Shanghai, Zhuhai (Guangdong), and Rizhao (Shandong). As of December 2025, it held 734 granted patents with an additional 237 pending, alongside 42 software copyrights. The firm has been recognized as a national-level “little giant” enterprise under China's specialized-and-sophisticated manufacturing program, and in 2024 began appearing in the S&P Global Sustainability Yearbook (China Edition). INT Medical's architecture is uncommon among Chinese medtech companies: it is a publicly traded corporation with a tightly held founder-leadership that acts as a corporate venture platform, not simply an R&D manufacturer. Dr. Liang's dual role as founder-CEO and de-facto capital allocator of the group's subsidiary portfolio concentrates investment authority alongside operating control — a hybrid structure that allows the firm to move into new therapy areas through subsidiary creation rather than external fund commitments.
General information
Firm type
Corporate Investor
Year founded
2006
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Block 2, No. 925 Jin Yuan Yi Road, Jiading District, Shanghai, China
Additional offices
Zhuhai, Guangdong, China · Rizhao, Shandong, China
Principals
Dr. Liang Dongke
Founder, Chairman and General Manager
Sector focus
Frequently asked questions
Who controls investment decisions at Shanghai INT Medical Instruments?
Dr. Liang Dongke exercises control as founder, Chairman, and General Manager. The investment posture flows through the parent company, which allocates capital to 24 subsidiaries spanning cardiovascular, neurovascular, and other interventional segments. There is no separate investment committee or external CIO.
How does the firm fund new ventures — direct subsidiary creation, LP commitments, or both?
Both. INT Medical primarily builds or acquires wholly owned subsidiaries to enter adjacent therapy areas. It also acts as a limited partner in specialist life-science funds; Altss research identifies commitments to vehicles managed by Ningbo Huaige Health Investment Management Partnership.
What role does OrbiMed play in the firm's investment strategy?
OrbiMed Advisors is a substantial shareholder and co-investor. The relationship links INT Medical to a global healthcare investment network, though specific co-investment vehicles or deal-level collaboration have not been publicly detailed.
Is Shanghai INT Medical Instruments a single-family office or a corporate venture platform?
It is a corporate investor, not a family office. The firm is a publicly listed operating company (HKEX: 1501) that retains founder control and deploys retained earnings into a portfolio of subsidiaries and select fund commitments.
Which therapeutic areas does the firm specifically target for investment and product development?
The firm targets cardiovascular, peripheral vascular, neurovascular, cardiac electrophysiology, structural heart, urology, orthopedics, and non-vascular interventional devices. Its subsidiary structure allows it to enter new segments through dedicated operating entities.
Does the firm maintain philanthropic structures separate from the corporate entity?
No dedicated philanthropic foundation is disclosed. The firm emphasizes corporate sustainability and has been included in the S&P Global Sustainability Yearbook (China Edition) from 2024 onward, but does not report a separate charitable vehicle.
How is the firm's manufacturing footprint organized across China?
INT Medical operates three production and research bases: its headquarters in Jiading District, Shanghai; a facility in Zhuhai, Guangdong; and a site in Rizhao, Shandong. This footprint supports its strategy of owning core manufacturing, mold-making, and sterilization capabilities in-house.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: